Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines. Headquartered in Watertown, Massachusetts, with research operations in Sweden, the company utilizes its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to match therapies to patients based on protein signatures rather than genetic mutations. Its lead clinical candidate, ACR-368, is a targeted small molecule inhibitor being evaluated in Phase 2 trials for endometrial, ovarian, and urothelial cancers.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Selling, General & Administrative Expenses
24,124
25,207
21,079
8,708
Research & Development Expenses
59,990
63,992
46,024
23,949
Operating Profit
(84,114)
(89,199)
(67,103)
(32,657)
Interest and Investment Income
6,479
9,201
7,037
—
Non-Operating Income
5,939
8,085
6,393
1,490
Total Non-Operating Income
12,418
17,286
13,430
1,490
Income Before Provision for Income Taxes
(71,696)
(71,913)
(53,673)
(31,167)
Consolidated Net Income
(71,696)
(71,913)
(53,673)
(31,167)
Net Income Attributable to Common Shareholders
(77,905)
(80,556)
(60,388)
(31,167)
Basic EPS
-2.02
-2.38
-2.74
-7.56
Diluted EPS
-2.02
-2.38
-2.74
-7.56
Basic Weighted Average Shares Outstanding
38,509
33,792
22,078
4,122
Diluted Weighted Average Shares Outstanding
38,509
33,792
22,078
4,122
Shares Outstanding
31,649
31,231
22,523
21,920
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
41,499
39,818
36,015
29,519
Short-Term Investments
77,083
139,662
91,443
98,232
Total Cash and Cash Equivalents
118,582
179,480
127,458
127,751
Other Current Assets
1,863
2,149
2,234
4,344
Total Current Assets
120,445
181,629
129,692
132,095
Net Property, Plant & Equipment
7,416
8,025
7,908
6,862
Long-Term Investments
—
5,089
—
41,881
Other Long-Term Assets
1,856
1,845
665
388
Total Assets
129,717
196,588
138,265
181,226
Accounts Payable
2,277
758
5,048
904
Accrued Expenses
12,215
15,399
7,378
4,886
Current Portion of Leases
1,172
1,057
877
726
Total Current Liabilities
15,664
17,214
13,303
6,516
Leases
1,537
2,588
3,767
4,235
Total Long-Term Liabilities
1,537
2,588
3,767
4,235
Total Liabilities
17,201
19,802
17,070
10,751
Common Stock
31
31
23
22
Additional Paid-in Capital
387,255
373,284
237,675
226,580
Accumulated Other Comprehensive Income
111
447
(83)
(95)
Retained Earnings
(274,881)
(196,976)
(116,420)
(56,032)
Total Common Shareholders' Equity
112,516
176,786
121,195
170,475
Total Shareholders' Equity
112,516
176,786
121,195
170,475
Total Liabilities and Shareholders' Equity
129,717
196,588
138,265
181,226
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(77,905)
(80,556)
(60,388)
(31,167)
Depreciation & Amortization
1,356
1,006
536
364
Share-Based Compensation Expense
14,720
14,288
11,618
2,185
Other Adjustments
590
(2,845)
(2,545)
33
Changes in Accounts Payable
1,536
(3,586)
3,609
(245)
Changes in Accrued Expenses
(3,353)
8,021
3,173
2,919
Changes in Other Operating Activities
(609)
(1,997)
1,356
(4,206)
Cash from Operating Activities
(63,665)
(65,669)
(42,641)
(30,117)
Capital Expenditure
(1,669)
(2,768)
(1,288)
(2,166)
Purchases of Investments
(81,731)
(202,926)
(56,528)
(150,178)
Proceeds from Sale of Investments
149,500
153,923
108,533
10,668
Cash from Investing Activities
66,100
(51,771)
50,717
(141,676)
Issuance of Common Shares
1
130,090
775
104,482
Repurchases of Common Shares
(750)
(2,520)
(1,297)
—
Net Issuance / (Repurchases) of Common Shares
(749)
127,570
(522)
104,482
Other Financing Activities
—
(6,543)
(1,032)
(2,773)
Cash from Financing Activities
(749)
121,027
(1,554)
101,709
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash